Tenecteplase for submassive PE: more conflicting evidence (TOPCOAT)
www.pulmccm.org
By Parth Rali, MD and Marvin Balaan, MD Submassive pulmonary emboli (PE) are those that are severe enough to produce right ventricular dysfunction on echocardiogram or elevated biomarkers (mainly troponin), but not hemodynamic instability (i.e., systemic blood pressure and cardiac output are preserved). The management of the patient with submassive PE is a matter of controversy with several recent trials looking at safety, dosing, and route of administration of tPA. The American College of Chest Physicians (ACCP) 2012 consensus guidelines
Tenecteplase for submassive PE: more conflicting evidence (TOPCOAT)
Tenecteplase for submassive PE: more…
Tenecteplase for submassive PE: more conflicting evidence (TOPCOAT)
By Parth Rali, MD and Marvin Balaan, MD Submassive pulmonary emboli (PE) are those that are severe enough to produce right ventricular dysfunction on echocardiogram or elevated biomarkers (mainly troponin), but not hemodynamic instability (i.e., systemic blood pressure and cardiac output are preserved). The management of the patient with submassive PE is a matter of controversy with several recent trials looking at safety, dosing, and route of administration of tPA. The American College of Chest Physicians (ACCP) 2012 consensus guidelines